Tigli Hulya, Yazici Hulya, Dalay Nejat
Department of Basic Oncology, Istanbul University, Oncology Institute 34390 Capa, Istanbul, Turkey.
Res Commun Mol Pathol Pharmacol. 2003;113-114:307-14.
Steroid hormones, especially androgens, are believed to play a key role in the etiology of prostate cancer. Therefore, polymorphisms in genes involved in the androgen metabolism may affect the risk of prostate cancer. One such gene is CYP17, which encodes the cytochrome P450c17alpha enzyme that mediates both 17alpha-hydroxylase and 17,20-lyase in the steroid biosynthesis pathway. A polymorphism in the 5'-promoter region of the CYP17 gene has been associated with increased risk for prostate cancer. The T to C transition in the risk allele creates a new recognition site for the restriction enzyme MspA1. In this study we investigated the distribution of this polymorphism in the Turkish population and its association with prostate cancer and benign prostatic hyperplasia. Genotype frequencies in the patients with prostate cancer or prostatic hyperplasia and the control group were not significantly different. Our data provide no evidence for an association between prostate cancer risk and the CYP17 gene polymorphism.
类固醇激素，尤其是雄激素，被认为在前列腺癌的病因中起关键作用。因此，参与雄激素代谢的基因多态性可能会影响前列腺癌的风险。其中一个这样的基因是CYP17，它编码细胞色素P450c17α酶，该酶在类固醇生物合成途径中介导17α-羟化酶和17,20-裂解酶。CYP17基因5'-启动子区域的多态性与前列腺癌风险增加有关。风险等位基因中的T到C转换为限制性酶MspA1创造了一个新的识别位点。在本研究中，我们调查了这种多态性在土耳其人群中的分布及其与前列腺癌和良性前列腺增生的关联。前列腺癌或前列腺增生患者与对照组的基因型频率没有显著差异。我们的数据没有提供前列腺癌风险与CYP17基因多态性之间存在关联的证据。
